Cyclooxygenase-2 and atherosclerosis

Current Opinion in Lipidology

Volumn 13, Issue 5, 2002, Pages 497-504

  Linton, MacRae F ^a,b   Fazio, Sergio ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; INDOMETACIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CONTROLLED STUDY; DIET; FETUS LIVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; WILD TYPE; ANIMAL; ARTERIOSCLEROSIS; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; MACROPHAGE; METABOLISM; PATHOLOGY; RESTENOSIS;

ANIMALIA;

ANIMALS; ARTERIOSCLEROSIS; CORONARY RESTENOSIS; CYCLOOXYGENASE 2; HUMANS; INFLAMMATION; ISOENZYMES; MACROPHAGES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, PROSTAGLANDIN;

EID: 0036774737     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200210000-00005     Document Type: Review

References (80)

1. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991; 1083:1-17.
2. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063-1073.
3. Raz A, Wyche A, Siegel N, Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 1988; 263:3022-3028.
4. Reed DW, Bradshaw WS, Xie W, Simmons DL. In vivo and in vitro expression of a non-mammalian cyclooxygenase-1. Prostaglandins 1996; 52:269-284.
5. Wu KK. Cyclooxygenase-2 induction in congestive heart failure friend or foe? Circulation 1998; 98:95-96.
6. Appleby SB, Ristimaki A, Nelson K, et al. Structure of the human cyclooxygenase-2 gene. Biochem J 1994; 302:723-737.
7. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24 (Suppl 49):15-19.
8. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155:1281-1291.
9. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19:646-655.
10. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995; 75:3A-10A.
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
12. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31:1240-1249.
13. Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. Br Med J 1994; 309:1215-1217.
14. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of selective inhibitors of COX-2. Proc Natl Acad Sci USA 1999; 96:272-277.
15. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735-741.
16. Wong E, Huang J, Tagari P, Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 2001; 157:393-402.
17. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102:840-845.
18. Vane JR. Biomedicine. Back to an aspirin a day? [letter; comment]. Science 2002; 296:474-475.
19. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-1528.
20. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
21. FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-442.
22. Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996; 93:4885-4890.
23. Kreuzer J, Denger S, Jahn L, et al. LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway. Arterioscler Thromb Vasc Biol 1996; 16:1481-1487.
24. Cao HJ, Wang HS, Zhang Y, et al. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem 1998; 273:29615-29625.
25. Callejas NA, Casado M, Diaz-Guerra MJ, etal. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 2001; 33(4):860-867
26. Shankavaram UT, Lai WC, Netzel-Arnett S, et al. Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem 2001; 276:19027-19032.
27. Wesley RB 2nd, Meng X, Godin D, Galis ZS. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 1998; 18:432-440.
28. Pomerantz KB, Nicholson AC, Hajjar DP. Signal transduction in atherosclerosis: second messengers and regulation of cellular cholesterol trafficking. Adv Exp Med Biol 1995; 369:49-64.
29. Yamagata K, Anderson KI, Kaufman WE, et al. Expression of a mitogen inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 1192:371-386.
30. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231(25):232-235.
31. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41:1591-1602.
32. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65:336-347.
33. Marnett LJ, Kalgutkar AS. Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. Curr Opin Chem Biol 1998; 2:482-490.
34. Chesebro JH, Webster MI, Zoldhelyi P, et al. Antithrombotic therapy and progression of coronary artery disease: antiplatelet versus antithrombins. Circulation 1992; 86:III-100-III-111.
35. Ridker PM, Manson JE, Gaziano JM, et al. Low dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114:835-839.
36. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
37. Mehta JL. Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clin Cardiol 1998; 21:879-884.
38. Bailey JM, Butler J. Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation. Atherosclerosis 1973; 17:515-522.
39. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105:1816-1823.
40. Eligini S, Colli S, Basso F, et al. Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages. Arterioscler Thromb Vasc Biol 1999; 19:1719-1725.
41. Mathur SN, Albright E, Field FJ. Decreased prostaglandin production by cholesterol-rich macrophages. J Lipid Res 1989; 30:1385-1395.
42. Faour WH, He Y, He QW, et al. Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1beta-treated human synovial fibroblasts. J Biol Chem 2001; 276:31720-31731.
43. Hinz B, Brune K, Pahl A. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000; 278:790-796.
44. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153:17-23.
45. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95:7614-7619.
46. Tontonoz P, Nagy L, Alvarez JGA, et al. PPAR-gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252.
47. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 2000; 275:28028-28032.
48. Smith LH, Boutaud O, Breyer M, et al. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol 2002; 22:983-988.
49. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
50. Pratico D, Tillmann C, Zhang ZB, et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001; 98:3358-3363.
51. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290:551-560.
52. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-1740.
53. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96:7563-7568.
54. Riendeau D, Charleson S, Cromlish W, et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol 1997; 75:1088-1095.
55. Purcell-Huynh DA, Farese Jr RV, Johnson DF, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995; 95:2246-2257.
56. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995; 36:2320-2328.
57. Krul ES, Napawan N, Butteiger DT, et al. Atherosclerosis is reduced in cholesterol-fed apoE(-/-) mice administered an ASBT inhibitor or a selective COX-2 inhibitor [online]. Arterioscler Thromb Vasc Biol 2002; 22:P409.
58. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272:3406-3410.
59. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation. Science 1995; 267:1034-1037.
60. Babaev VR, Fazio S, Gleaves LA, et al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest 1999; 103:1697-1705.
61. Babaev VR, Patel MB, Semenkovich CF, et al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem 2000; 275:26293-26299.
62. Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7:699-705.
63. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5:434-438.
64. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001; 7:738-741.
65. Saiura A, Sata M, Hirata Y, et al. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 2001; 7:382-383.
66. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8:403-409.
67. Terada N, Hamazaki T, Oka M, et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 2002; 416:542-545.
68. Wurmser AE, Gage FH. Stem cells: cell fusion causes confusion. Nature 2002; 416:485-487.
69. Huebner SB, Babaev VR, Zhu T, et al. Bone marrow stem cells are a source of smooth muscle and endothelial cells in atherosclerotic lesions [online]. Arterioscler Thromb Vasc Biol 2002; 22:P339.
70. Pablos JL, Santiago B, Carreira PE, et al. Cyclooxygenase-1 and -2 are expressed by human T cells. Clin Exp Immunol 1999; 115:86-90.
71. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Ann Rev Phamacol Toxicol 1998; 38:97-120.
72. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997; 24:6-8.
73. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47:403-411.
74. Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis. Front Biosci 2001; 6:D515-D525.
75. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104:2280-2288.
76. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
77. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation. Circulation 2002; 106:191-195.
78. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296:539-541.
79. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New Engl J Med 2001; 345:1809-1817.
80. Gaspoz J-M, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346:1800-1806.